收藏切换
Multidimensional value assessment framework for new anti-lung cancer drugs to support evidence-informed medical insurance decision-making
收藏切换
Chen PAN1, Yi-tian LI1, Qin-wen XU1, 2, Jing-yi MENG1, Guo-hua WANG3, Jin-song GENG1, *
Chinese Journal of New Drugs | 2026, 35(19) : 2061 - 2066
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(19): 2061-2066
Multidimensional value assessment framework for new anti-lung cancer drugs to support evidence-informed medical insurance decision-making
Full
Chen PAN1, Yi-tian LI1, Qin-wen XU1, 2, Jing-yi MENG1, Guo-hua WANG3, Jin-song GENG1, *
Affiliations
  • 1 Medical School of Nantong University, Nantong 226001, China
  • 2 Nantong First People’s Hospital, Nantong 226001, China
  • 3 Xuanwu Hospital Capital Medical University, Beijing 100053, China
Published: 2026-10-15 doi: 10.20251/j.cnki.1003-3734.2026.19.006
Outline
收藏切换
Objective:

To construct a multidimensional value assessment framework for novel drugs for lung cancer, thereby supporting evidence-informed decision-making for medical insurance reimbursement.

Methods:

First, literature on the value assessment of novel drugs for lung cancer was searched and reviewed. Based on a literature review and a focus group discussion, the framework was preliminarily constructed. Then, the Delphi method was used to determine the criteria, sub-criteria, weights, and value assessment methods. Finally, the feasibility of framework was verified through the value assessment of three novel drugs for lung cancer.

Results:

The constructed multidimensional value assessment framework for novel drugs for lung cancer consists of five core criteria, two contextualized criteria, and 20 sub-criteria. The core criteria include comparative effectiveness, comparative safety, affordability, economic value, and evidence quality, with comparative effectiveness having the highest weight. Among the sub-criteria of the core criteria, overall survival and progression-free survival have the highest weights. The contextual criteria are innovation and equity.

Conclusion:

The structured multidimensional value assessment framework provides a decision-support tool for medical insurance policymakers and helps to improve the scientific rigor and transparency of decision-making.

new anti-lung cancer drugs  /  medical insurance  /  evidence-informed decision-making  /  value assessment framework  /  multi-criteria decision analysis
潘晨, 李逸天, 许钦雯, 孟静怡, 王国华, 耿劲松. 支持医保知证决策的肺癌新药多维价值评估框架. 中国新药杂志, 2026 , 35 (19) : 2061 -2066 . DOI: 10.20251/j.cnki.1003-3734.2026.19.006
Chen PAN, Yi-tian LI, Qin-wen XU, Jing-yi MENG, Guo-hua WANG, Jin-song GENG. Multidimensional value assessment framework for new anti-lung cancer drugs to support evidence-informed medical insurance decision-making[J]. Chinese Journal of New Drugs, 2026 , 35 (19) : 2061 -2066 . DOI: 10.20251/j.cnki.1003-3734.2026.19.006
Year 2026 volume 35 Issue 19
69
9
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.19.006
  • Receive Date:2026-02-05
  • Online Date:2026-10-29
  • Published:2026-10-15
Article Data
Affiliations
History
  • Received:2026-02-05
Funding
Affiliations
    1 Medical School of Nantong University, Nantong 226001, China
    2 Nantong First People’s Hospital, Nantong 226001, China
    3 Xuanwu Hospital Capital Medical University, Beijing 100053, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.19.006
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT